BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med 2019;48:e159-74. [PMID: 30879894 DOI: 10.1016/j.lpm.2019.02.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang B, Li D, Jin X, Zhang K. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma. The International Journal of Biochemistry & Cell Biology 2020;128:105859. [DOI: 10.1016/j.biocel.2020.105859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shao YT, Ma L, Zhang TH, Xu TR, Ye YC, Liu Y. The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges. Curr Top Med Chem 2019;19:2143-57. [PMID: 31456522 DOI: 10.2174/1568026619666190828162217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technol Cancer Res Treat 2020;19:1533033820962117. [PMID: 33357065 DOI: 10.1177/1533033820962117] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ding J, Li H, Liu Y, Xie Y, Yu J, Sun H, Xiao D, Zhou Y, Bao L, Wang H, Gao C. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:698302. [PMID: 34804914 DOI: 10.3389/fonc.2021.698302] [Reference Citation Analysis]
5 Haller SD, Monaco ML, Essani K. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer. Viruses. 2020;12. [PMID: 33213031 DOI: 10.3390/v12111318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Nelson BS, Lin L, Kremer DM, Sousa CM, Cotta-Ramusino C, Myers A, Ramos J, Gao T, Kovalenko I, Wilder-Romans K, Dresser J, Davis M, Lee HJ, Nwosu ZC, Campit S, Mashadova O, Nicolay BN, Tolstyka ZP, Halbrook CJ, Chandrasekaran S, Asara JM, Crawford HC, Cantley LC, Kimmelman AC, Wahl DR, Lyssiotis CA. Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy. Cancer Metab 2020;8:1. [PMID: 31908776 DOI: 10.1186/s40170-019-0202-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
7 Miyata Y, Mukae Y, Harada J, Matsuda T, Mitsunari K, Matsuo T, Ohba K, Sakai H. Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers. Molecules 2020;25:E5252. [PMID: 33187225 DOI: 10.3390/molecules25225252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liang L, Ding Y, Yu Y, Liu K, Rao S, Ge Y, Zeng M. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study. BMC Med Imaging 2021;21:75. [PMID: 33902469 DOI: 10.1186/s12880-021-00605-4] [Reference Citation Analysis]
9 Ala M. Target c-Myc to treat pancreatic cancer. Cancer Biol Ther 2022;:1-17. [PMID: 34978469 DOI: 10.1080/15384047.2021.2017223] [Reference Citation Analysis]
10 Salapa J, Bushman A, Lowe K, Irudayaraj J. Nano drug delivery systems in upper gastrointestinal cancer therapy. Nano Converg 2020;7:38. [PMID: 33301056 DOI: 10.1186/s40580-020-00247-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Yu X, Zheng Q, Zhang M, Zhang Q, Zhang S, He Y, Guo W. A Prognostic Model of Pancreatic Cancer Based on Ferroptosis-Related Genes to Determine Its Immune Landscape and Underlying Mechanisms. Front Cell Dev Biol 2021;9:746696. [PMID: 34820374 DOI: 10.3389/fcell.2021.746696] [Reference Citation Analysis]
12 Wu P, Wang X, Ma Y, Xu X, Liu W, Sheng Z, Chen M, Zhou R, Zhang K, Goodin S, Zheng X, Li D. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. Bioorg Chem 2020;101:104022. [PMID: 32599367 DOI: 10.1016/j.bioorg.2020.104022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Pandya G, Kirtonia A, Sethi G, Pandey AK, Garg M. The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential. Biochim Biophys Acta Rev Cancer 2020;1874:188423. [PMID: 32871244 DOI: 10.1016/j.bbcan.2020.188423] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
14 Azari FS, Vollmer CM Jr, Roses RE, Keele L, DeMatteo RP, Drebin JA, Lee MK 4th. A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: Morbidity, mortality, and impact on future therapy. Surgery 2020;168:1026-31. [PMID: 32888713 DOI: 10.1016/j.surg.2020.06.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Guenther M, Haas M, Heinemann V, Kruger S, Westphalen CB, von Bergwelt-Baildon M, Mayerle J, Werner J, Kirchner T, Boeck S, Ormanns S. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study. Br J Cancer 2020;123:1370-6. [PMID: 32830200 DOI: 10.1038/s41416-020-01029-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Chen J, Li T, Liang J, Huang Q, Huang JD, Ke Y, Sun H. Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy. Biomed Pharmacother 2022;145:112443. [PMID: 34847476 DOI: 10.1016/j.biopha.2021.112443] [Reference Citation Analysis]
17 Chalabi-Dchar M, Fenouil T, Machon C, Vincent A, Catez F, Marcel V, Mertani HC, Saurin JC, Bouvet P, Guitton J, Venezia ND, Diaz JJ. A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate. NAR Cancer 2021;3:zcab032. [PMID: 34409299 DOI: 10.1093/narcan/zcab032] [Reference Citation Analysis]
18 Uehara M, Domoto T, Takenaka S, Bolidong D, Takeuchi O, Miyashita T, Minamoto T. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. Cancer Sci 2020;111:4405-16. [PMID: 32986894 DOI: 10.1111/cas.14668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Xue J, Yao Y, Yao Q, Tian X, Feng Y, Su H, Kong D, Cui C, Yan L, Hao C, Zhou T. Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma. Life Sci 2020;260:118302. [PMID: 32827543 DOI: 10.1016/j.lfs.2020.118302] [Reference Citation Analysis]
20 Ahn HM, Kim DG, Kim YJ. Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells. Biochem Biophys Res Commun 2020;527:568-73. [PMID: 32423820 DOI: 10.1016/j.bbrc.2020.04.118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Shi M, Zhou B, Yang SP. Nomograms for predicting overall survival and cancer-specific survival in young patients with pancreatic cancer in the US based on the SEER database. PeerJ 2020;8:e8958. [PMID: 32322444 DOI: 10.7717/peerj.8958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Verloy R, Privat-Maldonado A, Smits E, Bogaerts A. Cold Atmospheric Plasma Treatment for Pancreatic Cancer-The Importance of Pancreatic Stellate Cells. Cancers (Basel) 2020;12:E2782. [PMID: 32998311 DOI: 10.3390/cancers12102782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Luo X, Yu B, Jiang N, Du Q, Ye X, Li H, Wang WQ, Zhai Q. Chemotherapy-Induced Reduction of Neutrophil-to-Lymphocyte Ratio Is Associated With Better Survival in Pancreatic Adenocarcinoma: A Meta-Analysis. Cancer Control 2020;27:1073274820977135. [PMID: 33269614 DOI: 10.1177/1073274820977135] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Chen J, Bao Y, Song Y, Zhang C, Qiu F, Sun Y, Xin L, Cao J, Jiang Y, Luo J, Zhang C, Wang G, Li Q, Liu Y, Tong W, Huang P. Hypoxia-alleviated nanoplatform to enhance chemosensitivity and sonodynamic effect in pancreatic cancer. Cancer Lett 2021;520:100-8. [PMID: 34245853 DOI: 10.1016/j.canlet.2021.07.008] [Reference Citation Analysis]
25 Nie K, Zhang L, You Y, Li H, Guo X, Zhang Z, Zhang C, Ji Y. Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study. Ther Adv Med Oncol 2020;12:1758835920970843. [PMID: 33240399 DOI: 10.1177/1758835920970843] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Huart C, Chen JW, Le Calvé B, Michiels C, Wéra AC. Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer? Int J Mol Sci 2020;21:E4767. [PMID: 32635552 DOI: 10.3390/ijms21134767] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Mu W, Wang Z, Zöller M. Ping-Pong-Tumor and Host in Pancreatic Cancer Progression. Front Oncol 2019;9:1359. [PMID: 31921628 DOI: 10.3389/fonc.2019.01359] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
28 Kovalenko TF, Larionova TD, Antipova NV, Shakhparonov MI, Pavlyukov MS. The Role of Non-coding RNAs in the Pathogenesis of Glial Tumors. Acta Naturae 2021;13:38-51. [PMID: 34707896 DOI: 10.32607/actanaturae.11270] [Reference Citation Analysis]
29 Shang J, Han X, Zha H, Tao H, Li X, Yuan F, Chen G, Wang L, Ma J, Hu Y. Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade. Front Oncol 2021;11:585271. [PMID: 33718140 DOI: 10.3389/fonc.2021.585271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ahmed AA, Marchetti C, Ohnmacht SA, Neidle S. A G-quadruplex-binding compound shows potent activity in human gemcitabine-resistant pancreatic cancer cells. Sci Rep 2020;10:12192. [PMID: 32699225 DOI: 10.1038/s41598-020-68944-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
31 Scaria GS, Kren BT, Klein MA. Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response. Pharmaceuticals (Basel) 2020;13:E26. [PMID: 32033319 DOI: 10.3390/ph13020026] [Reference Citation Analysis]
32 Yang J, Xu J, Zhang B, Tan Z, Meng Q, Hua J, Liu J, Wang W, Shi S, Yu X, Liang C. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Int J Mol Sci 2021;22:10944. [PMID: 34681603 DOI: 10.3390/ijms222010944] [Reference Citation Analysis]
33 Mitachi K, Ariake K, Shima H, Sato S, Miura T, Maeda S, Ishida M, Mizuma M, Ohtsuka H, Kamei T, Igarashi K, Unno M. Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer. Sci Rep 2021;11:6541. [PMID: 33753854 DOI: 10.1038/s41598-021-86099-0] [Reference Citation Analysis]
34 Zhang Y, Xu G, Chen M, Wei Q, Zhou T, Chen Z, Shen M, Wang P. Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Front Oncol 2020;10:1018. [PMID: 32766130 DOI: 10.3389/fonc.2020.01018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Xu Z, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T, Neoptolemos JP. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Front Cell Dev Biol 2021;9:743908. [PMID: 34805152 DOI: 10.3389/fcell.2021.743908] [Reference Citation Analysis]
36 Holbrook MC, Goad DW, Grdzelishvili VZ. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions. Cancers (Basel) 2021;13:1171. [PMID: 33803211 DOI: 10.3390/cancers13051171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang G, Yang L, Gao J, Mu H, Song Y, Jiang X, Chen B, Cui R. Identification of Candidate Biomarker ASXL2 and Its Predictive Value in Pancreatic Carcinoma. Front Oncol 2021;11:736694. [PMID: 34692512 DOI: 10.3389/fonc.2021.736694] [Reference Citation Analysis]
38 He Y, Yue H, Cheng Y, Ding Z, Xu Z, Lv C, Wang Z, Wang J, Yin C, Hao H, Chen C. ALKBH5-mediated m6A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death Dis 2021;12:1121. [PMID: 34853296 DOI: 10.1038/s41419-021-04401-4] [Reference Citation Analysis]
39 Pekarek L, Fraile-Martinez O, Garcia-Montero C, Alvarez-Mon MA, Acero J, Ruiz-Llorente L, García-Honduvilla N, Albillos A, Buján J, Alvarez-Mon M, Guijarro LG, Ortega MA. Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives. Oncol Lett 2021;22:809. [PMID: 34630716 DOI: 10.3892/ol.2021.13070] [Reference Citation Analysis]
40 Brada LJH, Walma MS, Daamen LA, van Roessel S, van Dam RM, de Hingh IH, Liem MLS, de Meijer VE, Patijn GA, Festen S, Stommel MWJ, Bosscha K, Polée MB, Yung Nio C, Wessels FJ, de Vries JJJ, van Lienden KP, Bruijnen RC, Los M, Mohammad NH, Wilmink HW, Busch OR, Besselink MG, Quintus Molenaar I, van Santvoort HC; Dutch Pancreatic Cancer Group. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. J Surg Oncol 2021;124:589-97. [PMID: 34115379 DOI: 10.1002/jso.26567] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Chauhan SS, Shetty AB, Hatami E, Chowdhury P, Yallapu MM. Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells. Pharmaceutics 2020;12:E285. [PMID: 32235765 DOI: 10.3390/pharmaceutics12030285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos JP, Jäger D, Siveke J, Springfeld C. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. Genes Chromosomes Cancer 2021;60:373-84. [PMID: 33341987 DOI: 10.1002/gcc.22932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]